ES538727A0 - Un procedimiento para obtener un hibridoma selectivamente destructible (como divisional de la solicitud de patente de invencion num 521370 presentada el 11 de abril de 1983 - Google Patents

Un procedimiento para obtener un hibridoma selectivamente destructible (como divisional de la solicitud de patente de invencion num 521370 presentada el 11 de abril de 1983

Info

Publication number
ES538727A0
ES538727A0 ES538727A ES538727A ES538727A0 ES 538727 A0 ES538727 A0 ES 538727A0 ES 538727 A ES538727 A ES 538727A ES 538727 A ES538727 A ES 538727A ES 538727 A0 ES538727 A0 ES 538727A0
Authority
ES
Spain
Prior art keywords
hybridoma
divisional
procedure
patent application
filed april
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES538727A
Other languages
English (en)
Other versions
ES8604424A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hybritech Inc
Original Assignee
Hybritech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybritech Inc filed Critical Hybritech Inc
Publication of ES538727A0 publication Critical patent/ES538727A0/es
Publication of ES8604424A1 publication Critical patent/ES8604424A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
    • A61K51/109—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
ES538727A 1982-04-12 1984-12-18 Un procedimiento para obtener un hibridoma selectivamente destructible (como divisional de la solicitud de patente de invencion num 521370 presentada el 11 de abril de 1983 Expired ES8604424A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36778482A 1982-04-12 1982-04-12

Publications (2)

Publication Number Publication Date
ES538727A0 true ES538727A0 (es) 1986-02-01
ES8604424A1 ES8604424A1 (es) 1986-02-01

Family

ID=23448582

Family Applications (7)

Application Number Title Priority Date Filing Date
ES521370A Granted ES521370A0 (es) 1982-04-12 1983-04-11 Un procedimiento para obtener un polidoma.
ES527963A Expired ES8503441A1 (es) 1982-04-12 1983-12-12 Un procedimiento de inmunoensayo
ES533930A Expired ES8603080A1 (es) 1982-04-12 1984-07-02 Un procedimiento para obtener un polidoma
ES533931A Expired ES8506091A1 (es) 1982-04-12 1984-07-02 Un procedimiento para obtener un polidoma
ES537257A Expired ES8606655A1 (es) 1982-04-12 1984-10-31 Un procedimiento de inmunoensayo
ES538727A Expired ES8604424A1 (es) 1982-04-12 1984-12-18 Un procedimiento para obtener un hibridoma selectivamente destructible (como divisional de la solicitud de patente de invencion num 521370 presentada el 11 de abril de 1983
ES545247A Expired ES8607386A1 (es) 1982-04-12 1985-07-16 Un procedimiento para obtener un polidoma

Family Applications Before (5)

Application Number Title Priority Date Filing Date
ES521370A Granted ES521370A0 (es) 1982-04-12 1983-04-11 Un procedimiento para obtener un polidoma.
ES527963A Expired ES8503441A1 (es) 1982-04-12 1983-12-12 Un procedimiento de inmunoensayo
ES533930A Expired ES8603080A1 (es) 1982-04-12 1984-07-02 Un procedimiento para obtener un polidoma
ES533931A Expired ES8506091A1 (es) 1982-04-12 1984-07-02 Un procedimiento para obtener un polidoma
ES537257A Expired ES8606655A1 (es) 1982-04-12 1984-10-31 Un procedimiento de inmunoensayo

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES545247A Expired ES8607386A1 (es) 1982-04-12 1985-07-16 Un procedimiento para obtener un polidoma

Country Status (11)

Country Link
EP (1) EP0105360A4 (es)
JP (2) JPH0753119B2 (es)
AT (1) AT394577B (es)
AU (1) AU550486B2 (es)
CA (1) CA1213229A (es)
CH (1) CH672796A5 (es)
ES (7) ES521370A0 (es)
FI (1) FI834529A (es)
GB (4) GB2128631B (es)
IT (1) IT1219778B (es)
WO (1) WO1983003679A1 (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3177776B2 (ja) * 1988-09-27 2001-06-18 武田薬品工業株式会社 ハイブリッドモノクローナル抗体，抗体産生ポリドーマおよび抗体含有薬剤
US5292668A (en) * 1981-12-21 1994-03-08 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
CA1214123A (en) * 1983-01-20 1986-11-18 Masashi Matsui Cell lines for use in the preparation of hybridoma cells
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
EP0467416A1 (en) * 1983-09-01 1992-01-22 Hybritech Incorporated Antibody compositions of therapeutic agents having an extended serum half-life
WO1985004811A1 (en) * 1984-04-23 1985-11-07 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
NL8501219A (nl) * 1985-04-29 1986-11-17 Stichting Vrienden Van De Stic Immunologisch complex, de bereiding en toepassing daarvan.
JP2635343B2 (ja) 1986-04-14 1997-07-30 ザ・ジェネラル・ホスピタル・コーポレーション ヘテロ二官能性抗体および利用方法
US5453269A (en) * 1986-04-14 1995-09-26 The General Hospital Corporation Heterobifunctional antibodies having dual specificity for fibrin and thrombolylic agents and methods of use
FR2604092B1 (fr) * 1986-09-19 1990-04-13 Immunotech Sa Immunoreactifs destines a cibler les cellules animales pour leur visualisation ou leur destruction in vivo
GB8626412D0 (en) * 1986-11-05 1986-12-03 Clark M R Antibodies
GB8626413D0 (en) * 1986-11-05 1986-12-03 Gilliland L K Antibodies
US5053226A (en) * 1987-07-15 1991-10-01 Board Of Regents, The University Of Texas System Monoclonal antibodies binding platinum complexes
ATE108068T1 (de) * 1987-09-23 1994-07-15 Bristol Myers Squibb Co Antikörper-heterokonjugate zur töting von hiv- infizierten zellen.
GB2218100A (en) * 1988-03-02 1989-11-08 Erling Sundrehagen Conjugates for the detection and/or quantification of antigenic substances in body fluids
US4892824A (en) * 1988-03-15 1990-01-09 Synbiotics Corporation Fast track method for producing monoclonal bi-specific immunoglobulins
US5372812A (en) * 1988-04-04 1994-12-13 The General Hospital Corporation Composition and method for acceleration of clot lysis
US5582862A (en) 1988-04-04 1996-12-10 General Hospital Corporation Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
JPH02196799A (ja) * 1988-04-08 1990-08-03 Agency Of Ind Science & Technol 抗ヒト癌蛋白複合体
US5851527A (en) * 1988-04-18 1998-12-22 Immunomedics, Inc. Method for antibody targeting of therapeutic agents
IT1235349B (it) * 1988-12-23 1992-06-30 Biodata Spa Saggio immunologico per determinazioni in fase omogenea
CA2006408A1 (en) * 1988-12-27 1990-06-27 Susumu Iwasa Bispecific monoclonal antibody, its production and use
US5217713A (en) * 1988-12-27 1993-06-08 Takeda Chemical Industries, Ltd. Cytotoxic bispecific monoclonal antibody, its production and use
WO1990012109A1 (en) * 1989-03-30 1990-10-18 Board Of Regents, The University Of Texas System Monoclonal antibodies binding platinum complexes
FR2652004B1 (fr) * 1989-09-21 1994-10-28 Immunotech Partners Nouveaux derives hydrophiles, application au diagnostic et a la therapeutique, kits diagnostiques ou therapeutiques et reactifs immunologiques.
WO1991012023A2 (en) * 1990-02-16 1991-08-22 Boston Biomedical Research Institute Hybrid reagents capable of selectively releasing molecules into cells
TW212184B (es) * 1990-04-02 1993-09-01 Takeda Pharm Industry Co Ltd
WO1992019973A1 (en) * 1991-04-26 1992-11-12 Surface Active Limited Novel antibodies, and methods for their use
GB9316369D0 (en) * 1993-08-06 1993-09-22 Surface Active Ltd Diagnostic method
US5541110A (en) 1994-05-17 1996-07-30 Bristol-Myers Squibb Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica
GB9421468D0 (en) * 1994-10-18 1994-12-07 Surface Active Ltd Biosensor
EP0937146A2 (en) * 1996-09-20 1999-08-25 The General Hospital Corporation Composition and method for enhancing fibrinolysis using antibodies to alpha-2-antiplasmin
US20020132274A1 (en) 2001-01-17 2002-09-19 Nevalainen Marja T. Diagnostic and monitorings methods for cancer
US7659241B2 (en) 2002-07-31 2010-02-09 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
BR122018071808B8 (pt) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugado
EP1740530B8 (en) 2004-03-16 2017-03-01 Temple University - Of The Commonwealth System of Higher Education Substituted phenoxy- and phenylthio-derivatives for treating proliferative disorders
JP2008519863A (ja) 2004-11-12 2008-06-12 シアトル ジェネティクス インコーポレイティッド Ｎ末端にアミノ安息香酸単位を有するオーリスタチン
CA2605507C (en) 2005-04-19 2016-06-28 Seattle Genetics, Inc. Humanized anti-cd70 binding agents and uses thereof
PT3248613T (pt) 2005-07-18 2022-03-16 Seagen Inc Conjugados de ligante de fármaco e beta-glucuronida
PT2099823E (pt) 2006-12-01 2014-12-22 Seattle Genetics Inc Agentes de ligação ao alvo variantes e suas utilizações
ZA200904482B (en) 2007-01-22 2010-09-29 Genentech Inc Polyelectrolyte precipitation and purification of antibodies
CA2975228C (en) 2008-05-02 2020-07-21 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
WO2011133658A1 (en) 2010-04-22 2011-10-27 Boston Medical Center Corporation Compositions and methods for targeting and delivering therapeutics into cells
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
MX368258B (es) 2013-03-15 2019-09-25 Zymeworks Inc Compuestos citotoxicos y antimitoticos y metodos de uso de los mismos.
WO2015053381A1 (ja) * 2013-10-10 2015-04-16 幸成 加藤 抗ポドプラニン抗体
CN106255513B (zh) 2013-12-27 2022-01-14 酵活有限公司 用于药物偶联物的含磺酰胺连接系统
IL287645B2 (en) 2014-09-17 2024-04-01 Zymeworks Bc Inc Cytotoxic and anti-mitotic compounds and methods for their use
TWI618697B (zh) 2015-11-03 2018-03-21 財團法人工業技術研究院 化合物、連接子－藥物、及配體－藥物耦合體
EA201892040A1 (ru) 2016-03-25 2019-04-30 Сиэтл Дженетикс, Инк. Способ получения пегилированных соединений лекарственный препарат - линкер и их промежуточных соединений
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
CA3056134A1 (en) 2017-03-24 2018-09-27 Seattle Genetics, Inc. Process for the preparation of glucuronide drug-linkers and intermediates thereof
WO2018209239A1 (en) 2017-05-11 2018-11-15 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
CN112638947B (zh) 2018-08-30 2022-09-30 上海斯丹赛生物技术有限公司 用于治疗实体瘤的嵌合抗原受体细胞
WO2020229982A1 (en) 2019-05-10 2020-11-19 Takeda Pharmaceutical Company Limited Antibody drug conjugates
TW202138388A (zh) 2019-12-30 2021-10-16 美商西根公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
US12076343B2 (en) 2020-02-19 2024-09-03 Innovative Cellular Therapeutics Holdings, Ltd. Engineered safety in cell therapy
US12043654B2 (en) 2020-06-02 2024-07-23 Innovative Cellular Therapeutics Holdings, Ltd. Anti-GCC antibody and CAR thereof for treating digestive system cancer
IL302390A (en) 2020-11-09 2023-06-01 Takeda Pharmaceuticals Co Drug antibody conjugates
US12030888B2 (en) 2021-02-24 2024-07-09 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof
MX2023013915A (es) 2021-06-29 2024-01-25 Seagen Inc Métodos para tratar el cáncer con una combinación de un anticuerpo anti-cd70 no fucosilado y un antagonista de cd47.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4130634A (en) * 1974-03-15 1978-12-19 University Of Illinois Foundation Method for detecting and quantifying antigens
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies

Also Published As

Publication number Publication date
ES8504461A1 (es) 1985-04-16
IT1219778B (it) 1990-05-24
FI834529A0 (fi) 1983-12-09
JPH0753600A (ja) 1995-02-28
ATA901883A (de) 1991-10-15
JPS6312276A (ja) 1988-01-19
GB2167086A (en) 1986-05-21
IT8320548A0 (it) 1983-04-12
GB2168998A (en) 1986-07-02
GB2169921A (en) 1986-07-23
WO1983003679A1 (en) 1983-10-27
EP0105360A4 (en) 1986-07-08
ES8606655A1 (es) 1986-04-01
GB2169921B (en) 1987-03-04
ES533931A0 (es) 1985-06-16
EP0105360A1 (en) 1984-04-18
ES545247A0 (es) 1986-05-16
AU550486B2 (en) 1986-03-20
CA1213229A (en) 1986-10-28
ES533930A0 (es) 1985-12-01
ES537257A0 (es) 1986-04-01
CH672796A5 (es) 1989-12-29
ES527963A0 (es) 1985-02-16
ES8506091A1 (es) 1985-06-16
GB2128631A (en) 1984-05-02
ES8604424A1 (es) 1986-02-01
GB8332646D0 (en) 1984-01-11
JP2562002B2 (ja) 1996-12-11
AU1555983A (en) 1983-11-04
GB2128631B (en) 1987-02-25
GB8530310D0 (en) 1986-01-22
ES8503441A1 (es) 1985-02-16
FI834529A (fi) 1983-12-09
GB8530309D0 (en) 1986-01-22
ES521370A0 (es) 1985-04-16
GB2168998B (en) 1987-03-04
AT394577B (de) 1992-05-11
ES8607386A1 (es) 1986-05-16
GB2167086B (en) 1987-03-04
GB8530308D0 (en) 1986-01-22
JPH0753119B2 (ja) 1995-06-07
ES8603080A1 (es) 1985-12-01

Similar Documents

Publication Publication Date Title
ES538727A0 (es) Un procedimiento para obtener un hibridoma selectivamente destructible (como divisional de la solicitud de patente de invencion num 521370 presentada el 11 de abril de 1983
ES523083A0 (es) Un procedimiento para preparar nuevos derivados de imidazo (4,5-c) piridina (como divisional de la solicitud de patente de invencion num. 517.193, presentada el 8 de noviembre de 1982)
ES551367A0 (es) Un procedimiento para preparar agentes quelantes (ligandos) del tipo de poliaminoditioles (como divisional de la solicitud de patente de invencion no. 542.678, presentada el 29 de abril de 1985)
ES522843A0 (es) "un metodo de preparacion de nuevas sulfonamidas sustituidas" nota: se solicita como divisional de la patente de invencion n 516.504.
ES522450A0 (es) Un procedimiento para la produccion de un fenilurazol condensado.(como divisional de la patente numero 515.806)
ES551319A0 (es) Un aparato para producir clinker de cemento blanco (como divisional de la solicitud de patente de invencion num. 544.021, presentada el 10.06.1985)
AR241082A1 (es) Nuevos derivados de pirazol utiles como agentes herbicidas, las composiciones herbicidas que los contienen y los procedimientos para producir estos derivados de pirazol".
ES523661A0 (es) Procedimiento para preparar fenoxipiridinas sulfuro-sustituidas teniendo actividad antiviral. desglose de la patente n 514.940.
ES540748A0 (es) Un procedimiento para la preparacion de nuevos 2,5-diaril-tetrahidrotiofenos y analogos de los mismos.
ES523345A0 (es) Procedimiento para la preparacion de cis yno trans hidroxiiminooctahidroindolo(2,3-a)-quinolizina racemicos (como divisional de la solicitud de patente de invencion num. 513.016, presentada el 11 de junio de 1982)
MX161306A (es) Procedimiento para la preparacion de 1,2,dicloretano
ES540173A0 (es) Procedimiento para la obtencion de nuevos 1,3,2-dioxaborina-nos
ES509168A0 (es) "procedimiento para la preparacion de derivados de fenoxi-aminopropanol substituidos" como divisional de la patente de invencion n 502.649 del 1 junio 1981.
ES522801A0 (es) "un procedimiento para la preparacion de glutation" (como divisional de la solicitud de patente de invencion numero 514.571, presentada el 30 de julio de 1982)
ES289054Y (es) Juego de elementos de construccion para estructuras con bas-tidor para la construccion de fachadas,cenadores,invernade- ros o analogos
ES527155A0 (es) Procedimiento para la preparacion de n-pteridinil-ureas(como divisional de la patente numero 521.331)
ES534980A0 (es) Mejoras en el objeto de la patente principal n 528.903, por: mejoras introducidas en los mecanismos para movimiento de extremidades en los munecos
MX160807A (es) Procedimiento para la preparacion de 1,2-dicloroetano
ES514848A0 (es) "procedimiento para preparar el herbicida fenmedifam".
ES533949A0 (es) Mejoras en el objeto de la patente de invencion n 531.764 que se refiere a procedimiento de obtencion de nuevas sulfonamidinas
IT8454052V0 (it) Punteria idraulica di tipo perfezionato
ES528324A0 (es) Procedimiento para la preparacion de 1,2-dicloroetano
ES509167A0 (es) "un procedimiento para la preparacion de cicloalca 4,5 pirrolo 2,3-g-isoquinolinas" como divisional de la patente de invencion n 499.861 del 27-2-81.
ES487588A0 (es) Procedimiento de preparacion de ditiocarbamatos.(como divisional de la patente numero 486050)
ES267808Y (es) "nudo para el montaje de estructuras".

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 19970401